Details

Autor(en) / Beteiligte

• Kimball, Alexa B
• Okun, Martin M
• Williams, David A
• Gottlieb, Alice B
• Papp, Kim A
• Zouboulis, Christos C
• Armstrong, April W
• Kerdel, Francisco
• Gold, Michael H
• Forman, Seth B
• Korman, Neil J
• Giamarellos-Bourboulis, Evangelos J
• Crowley, Jeffrey J
• Lynde, Charles
• Reguiai, Ziad
• Prens, Errol-Prospero
• Alwawi, Eihab
• Mostafa, Nael M
• Pinsky, Brett
• Sundaram, Murali
• Gu, Yihua
• Carlson, Dawn M
• Jemec, Gregor B.E

Titel

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Ist Teil von

• The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Hidradenitis suppurativa is a painful, chronic inflammatory skin disease. In two double-blind, placebo-controlled trials, treatment with adalimumab resulted in significantly increased rates of clinical response at week 12. Rates of serious adverse events were similar between groups. Hidradenitis suppurativa, also known as acne inversa, is a painful, chronic inflammatory skin disease 1 – 3 characterized by multifocal, recurrent nodules, abscesses, and fistulas, predominantly affecting the axillary, inguinal, breast-fold, and anogenital regions. 4 The prevalence of self-reported disease is 1% in Western Europe. 1 , 5 The average interval from the onset of symptoms to diagnosis is 7.2 years. 6 Women are affected 2 to 5 times as frequently as men, and the disease may be more common in blacks than in whites. 1 , 7 Disease severity ranges from mild (localized lesions) to severe (multiple areas of widely dispersed lesions, including interconnected sinus tracts and . . .